Drugs / MMF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02722668 Background | May 2017 → Feb 2023 | Burkitt lymphoma, Hodgkins lymphoma, T-cell and NK-cell neoplasm, T-cell non-Hodgkin lymphoma +12 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02722668 ↗ |
| Route | Intravenous | “Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg” NCT02722668 ↗ |
| Route | Oral | “Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg” NCT02722668 ↗ |